Guardant Health Inc (GH) - Total Assets
Based on the latest financial reports, Guardant Health Inc (GH) holds total assets worth $1.92 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Guardant Health Inc to assess how comfortably operating cash covers total debt obligations.
Guardant Health Inc - Total Assets Trend (2016–2025)
This chart illustrates how Guardant Health Inc's total assets have evolved over time, based on quarterly financial data. See GH net asset value for net asset value and shareholders' equity analysis.
Guardant Health Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Guardant Health Inc's total assets of $1.92 Billion consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.8% |
| Accounts Receivable | $137.85 Million | 6.9% |
| Inventory | $85.88 Million | 4.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.92 Million | 1.3% |
| Goodwill | $77.26 Million | 3.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Guardant Health Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guardant Health Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guardant Health Inc's current assets represent 72.8% of total assets in 2025, a decrease from 88.4% in 2016.
- Cash Position: Cash and equivalents constituted 18.8% of total assets in 2025, down from 28.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
Guardant Health Inc Competitors by Total Assets
Key competitors of Guardant Health Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Guardant Health Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.68 | 4.11 | 19.57 |
| Quick Ratio | 4.39 | 3.76 | 19.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.08 Billion | $701.27 Million | $1.79 Billion |
Guardant Health Inc - Advanced Valuation Insights
This section examines the relationship between Guardant Health Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 55.67 |
| Latest Market Cap to Assets Ratio | 6.30 |
| Asset Growth Rate (YoY) | 35.5% |
| Total Assets | $2.01 Billion |
| Market Capitalization | $12.69 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Guardant Health Inc's assets at a significant premium (6.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Guardant Health Inc's assets grew by 35.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Guardant Health Inc (2016–2025)
The table below shows the annual total assets of Guardant Health Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.01 Billion | +35.54% |
| 2024-12-31 | $1.49 Billion | -16.84% |
| 2023-12-31 | $1.79 Billion | +10.96% |
| 2022-12-31 | $1.61 Billion | -26.97% |
| 2021-12-31 | $2.20 Billion | -2.96% |
| 2020-12-31 | $2.27 Billion | +136.02% |
| 2019-12-31 | $962.53 Million | +63.86% |
| 2018-12-31 | $587.40 Million | +71.29% |
| 2017-12-31 | $342.94 Million | +194.20% |
| 2016-12-31 | $116.56 Million | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more